Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methylenedioxymetamfetamine - Awakn Life Sciences

Drug Profile

Methylenedioxymetamfetamine - Awakn Life Sciences

Alternative Names: 3,4-methylenedioxymethamphetamine; Ecstasy- Awakn Life Sciences; MDMA ZYDIS; MDMA- Awakn Life Sciences; Methylenedioxymetamfetamine- Awakn Life Sciences; Midomafetamine - Awakn Life Sciences

Latest Information Update: 09 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Awakn Life Sciences
  • Class Amines; Amphetamines; Behavioural disorder therapies; Benzodioxoles; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Alcoholism

Most Recent Events

  • 05 Jan 2024 MAPS is now called Lykos Therapeutics
  • 29 Aug 2022 Awakn life sciences plans a phase IIb randomized controlled trial (RCT) for Alcoholism in the UK and Europe in 2023 (Awakn life sciences website, August 2022)
  • 25 Aug 2022 Phase-II clinical trials in Alcoholism in Canada (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top